Long-term results of a phase-II-pilot trial on preoperative high-dose chemotherapy with stem cell rescue in patients with cancer of the upper gastrointestinal tract

2001 ◽  
Author(s):  
Wolfgang Berdel ◽  
Torsten Heldmann ◽  
Eckhard Thiel
Keyword(s):  
Stem Cell ◽  
Gastrointestinal Tract ◽  
Pilot Trial ◽  
High Dose Chemotherapy ◽  
Long Term Results ◽  
High Dose ◽  
Patients With Cancer ◽  
Stem Cell Rescue ◽  
Upper Gastrointestinal

scholarly journals Paclitaxel-Based High-Dose Chemotherapy with Autologous Stem Cell Rescue for Relapsed Germ Cell Tumor: Clinical Outcome and Quality of Life in Long-Term Survivors

2013 ◽  
Vol 11 (2) ◽  
pp. 121-127 ◽  
Author(s):  
Sumanta K. Pal ◽  
Jonathan Yamzon ◽  
Virginia Sun ◽  
Courtney Carmichael ◽  
Junmi Saikia ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Stem Cell ◽  
Clinical Outcome ◽  
High Dose Chemotherapy ◽  
Cell Tumor ◽  
High Dose ◽  
Stem Cell Rescue ◽  
Long Term Survivors

High dose chemotherapy with autologous stem cell rescue (ASCR) for recurrent medulloblastoma

2006 ◽  
Vol 24 (18_suppl) ◽  
pp. 11507-11507
Author(s):  
B. Diez ◽  
M. Garcia Lombardi ◽  
G. Chantada ◽  
C. Dengra ◽  
D. Fernandez Sasso ◽  
...  
Keyword(s):  
Stem Cell ◽  
Median Time ◽  
Area Under The Curve ◽  
High Dose Chemotherapy ◽  
Local Relapse ◽  
High Dose ◽  
Term Survival ◽  
Stem Cell Rescue ◽  
Autologous Stem Cell Rescue

11507 Background: Medulloblastoma is a highly lethal disease when it recurs and very few patients survive with conventional treatment. This study evaluated the use of high-dose carboplatin, thiotepa, and etoposide with autologous stem-cell rescue (ASCR) in patients with recurrent medulloblastoma. Methods: Between 8/97 and 8/05 14 patients (M/F 12/2) with recurrent medulloblastoma, aged 2 to 33 years (median, 10.5 years) at ASCR, were treated. Thirteen had relapsed after chemotherapy and craniospinal + posterior fossa irradiation and one after chemotherapy (Baby POG) at a median time of 19 months (7 to 148). One had a local relapse and 13 had dissemination at relapse (M1: 1, M2: 7 and M3: 5) Chemotherapy consisted of carboplatin 500 mg/m2 (or area under the curve = 7 mg/ml × min via Calvert formula) on days −8, −7, −6; and thiotepa 300 mg/m2 and etoposide 250 mg/m2 on days −5, −4, and −3 respectively; followed by ASCR on day 0. Results: Four patients died of treatment-related toxicities at 0, +23, +42 and +51 days post ASCR (bacterial sepsis in 2, CMV infection in 1 and CNS hemorrhage in 1). It should be remarked that all the toxic deaths were observed in patients auto grafted before October 2000. Five of 14 patients (35%) are event-free survivors at a median of 70 months post-ASCR (range: 5 to 86 months). Tumor recurred in the remaining 5 patients at a median time of 2 months post ASCR (2 to 15). All died at +23, +16, +12, +9 and +4 month post ASCR. Conclusions: Our results seem consistent with those published by Dunkel IJ (J. Clin Oncol; 16:222 - 8 1998) and argue about the efficacy of high dose chemotherapy with ASCR to provide long-term survival for some patients with recurrent medulloblastoma. No significant financial relationships to disclose.

Long-term physical and psychological sequelae in patients treated with high-dose chemotherapy with peripheral stem cell rescue

1997 ◽  
Vol 33 ◽  
pp. S61
Author(s):  
R. Caial ◽  
A. Calvo ◽  
J.I. Mayordomo ◽  
D. Isla ◽  
M. Alonso ◽  
...  
Keyword(s):  
Stem Cell ◽  
High Dose Chemotherapy ◽  
High Dose ◽  
Psychological Sequelae ◽  
Peripheral Stem Cell ◽  
Stem Cell Rescue

NCOG-36. LONG-TERM SURVIVAL AND COGNITIVE FUNCTION FOLLOW UP OF PRIMARY CNS LYMPHOMA TREATED WITH R-MVP FOLLOWED BY HIGH DOSE CHEMOTHERAPY WITH AUTOLOGOUS STEM CELL TRANSPLANT CONSOLIDATION

2021 ◽  
Vol 23 (Supplement_6) ◽  
pp. vi159-vi160
Author(s):  
Kate Therkelsen ◽  
Christian Grommes
Keyword(s):  
Stem Cell ◽  
Complete Response ◽  
High Dose Chemotherapy ◽  
High Dose ◽  
Consolidation Therapy ◽  
Term Survival ◽  
Stem Cell Rescue ◽  
Long Term Follow Up

Abstract BACKGROUND Primary central nervous system lymphoma (PCNSL) is a rare central nervous system malignancy, and long-term follow up studies are uncommon. First line therapy is based on high-dose methotrexate and different consolidation therapy options. This is a long-term follow up study of PCNSL patients enrolled in a prospective trial using R-MPV chemotherapy regimen followed by high dose chemotherapy and autologous stem cell rescue to determine long-term survival and cognitive effects. METHODS From June 2005 to September 2011, 32 newly diagnosed immunocompentent PCNSL were enrolled. Patients received 5-7 doses of rituximab (500mg/m2), methotrexate (3.5 gm/m2), procarbazine (100mg/m2), and vincristine (1.4mg/m2) (R-MVP). Consolidation therapy consisted of high dose chemotherapy (HDC) with thiotepa (250 mg/m2), busulfan (3.2 mg/kg), and cyclophosphamide (60 mg/kg), followed by autologous stem cell rescue (ASCT) in those with partial or complete response to R-MVP. Long-term follow-up status including disease status, cognitive status (KPS, NANO score), and leukoencephalopathy (modified Fazkas Scale) were collected. RESULTS 26 of 36 underwent HDC and ACST. Of those, 3 died due to treatment related effects; 2 died of disease progression within two years after ASCT. After a median follow-up of 10.5 years, none of the remaining 21 patients progressed. At the time of last follow up, the median KPS was 90, compared to 80 at time of ASCT. The median NANO score and leukoencephalopathy score post ASCT and at follow-up did not change. Of note, 2 of 4 patients with a partial or complete response to R-MVP that elected not to proceed with HDC-ASCT consolidation, experienced progression at a mean of 52 months. CONCLUSION Long-term follow up demonstrates that treatment was tolerated well with stable leukoencephalopathy on MRI and good performance status. Disease recurrence 2 years after HDC with ASCT consolidation was not observed.

Long-Term Follow Up of High-Dose Chemotherapy With Autologous Stem Cell Rescue in Adults With Ewing Tumor

2005 ◽  
Vol 28 (3) ◽  
pp. 301-309 ◽  
Author(s):  
Val??rie Laurence ◽  
Jean-Yves Pierga ◽  
Sophie Barthier ◽  
Antoine Babinet ◽  
Claire Alapetite ◽  
...  
Keyword(s):  
Stem Cell ◽  
High Dose Chemotherapy ◽  
High Dose ◽  
Stem Cell Rescue ◽  
Long Term Follow Up ◽  
Autologous Stem Cell Rescue ◽  
Ewing Tumor
Sign in / Sign up

Export Citation Format

Share Document